These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 35221289)

  • 21. Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study.
    Stottlemyer BA; McDermott MC; Minogue MR; Gray MP; Boyce RD; Kane-Gill SL
    Ther Adv Drug Saf; 2023; 14():20420986231181334. PubMed ID: 37332887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antisense oligonucleotide: A promising therapeutic option to beat COVID-19.
    Quemener AM; Galibert MD
    Wiley Interdiscip Rev RNA; 2022 Jul; 13(4):e1703. PubMed ID: 34842345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases.
    Verma A
    Ann Indian Acad Neurol; 2018; 21(1):3-8. PubMed ID: 29720791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the Inhibition of Organic Anion Transporter on Tricyclo-DNA-Mediated Exon Skipping in the
    Bizot F; Tensorer T; Garcia L; Goyenvalle A
    Nucleic Acid Ther; 2023 Dec; 33(6):374-380. PubMed ID: 37967388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
    Beninger P; Murray M
    Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical Evaluation of the Renal Toxicity of Oligonucleotide Therapeutics in Mice.
    Echevarría L; Goyenvalle A
    Methods Mol Biol; 2022; 2434():371-384. PubMed ID: 35213032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development.
    Quemener AM; Centomo ML; Sax SL; Panella R
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases.
    Aoki Y; Wood MJA
    J Neuromuscul Dis; 2021; 8(6):869-884. PubMed ID: 34092651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in Dystrophinopathy Diagnosis and Therapy.
    Saad FA; Siciliano G; Angelini C
    Biomolecules; 2023 Aug; 13(9):. PubMed ID: 37759719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mining FDA drug labels using an unsupervised learning technique--topic modeling.
    Bisgin H; Liu Z; Fang H; Xu X; Tong W
    BMC Bioinformatics; 2011 Oct; 12 Suppl 10(Suppl 10):S11. PubMed ID: 22166012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigating drug repositioning opportunities in FDA drug labels through topic modeling.
    Bisgin H; Liu Z; Kelly R; Fang H; Xu X; Tong W
    BMC Bioinformatics; 2012; 13 Suppl 15(Suppl 15):S6. PubMed ID: 23046522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases.
    Rodrigues M; Yokota T
    Methods Mol Biol; 2018; 1828():31-55. PubMed ID: 30171533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System.
    Wang G; Wang J; Du R; Wang Y; Li Z
    Paediatr Drugs; 2024 Mar; 26(2):175-185. PubMed ID: 38153627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
    Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
    Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dataset of 200 structured product labels annotated for adverse drug reactions.
    Demner-Fushman D; Shooshan SE; Rodriguez L; Aronson AR; Lang F; Rogers W; Roberts K; Tonning J
    Sci Data; 2018 Jan; 5():180001. PubMed ID: 29381145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project.
    Ladewski LA; Belknap SM; Nebeker JR; Sartor O; Lyons EA; Kuzel TC; Tallman MS; Raisch DW; Auerbach AR; Schumock GT; Kwaan HC; Bennett CL
    J Clin Oncol; 2003 Oct; 21(20):3859-66. PubMed ID: 14551305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development.
    Dhuri K; Bechtold C; Quijano E; Pham H; Gupta A; Vikram A; Bahal R
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32604776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Traditional and novel non-statin lipid-lowering drugs.
    Jain P
    Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S38-S43. PubMed ID: 37979722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.